Elizabeth A. Davidson

Elizabeth A. Davidson

Auto-generated profile, based on publicly available information

Elizabeth A. Davidson

Child Study Center, Yale University School of Medicine, New Haven, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2026 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
MGMeilin Fernandez Garcia
Meilin Fernandez Garcia
KTKayla Townsley
Kayla Townsley
APApril Pruitt
April Pruitt
EDElizabeth A. Davidson
Elizabeth A. Davidson
NBNovin Balafkan
Novin Balafkan
KBKristen Brennand
Kristen Brennand
Diverse risk genes have been identified for neurodevelopmental disorders (NDDs), but how these genes converge on similar biological pathways in neurons, and thus give rise to similar phenotypes, is unclear. Here we apply a pooled CRISPR approach to successfully target 23 NDD loss-of-function genes with roles in chromatin biology and examine convergent effects on gene expression across human induced pluripotent stem cell-derived neural progenitor cells, glutamatergic neurons and GABAergic neurons. Points of convergence vary between these cell types, with the greatest number of convergent genes and strongest convergent networks in mature glutamatergic neurons, where they broadly represent synaptic, epigenetic and, unexpectedly, mitochondrial pathways. The most convergent networks were observed between NDD genes with shared biological annotations, clinical associations and co-expression patterns in human post-mortem brain. Drugs that were predicted to reverse convergent transcriptomic signatures and/or arousal and sensory processing behaviors ameliorated behavioral phenotypes in zebrafish NDD gene mutants. These results suggest that convergent effects of NDD risk genes could provide clinically useful insights.